Curanex Pharmaceuticals Inc Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Curanex Pharmaceuticals Inc (CURX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $1.35 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-08-14
- Curanex Pharmaceuticals Inc valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2026-06-30 was $693.16K.
- Curanex Pharmaceuticals Inc valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2026-03-31 was $661.55K, a 0.00% change year-over-year.
- Curanex Pharmaceuticals Inc valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2025-12-31 was $1.24M.
- Curanex Pharmaceuticals Inc valuation allowance, deferred tax asset, increase (decrease), amount for the quarter ending 2025-09-30 was $70.27K.
- Curanex Pharmaceuticals Inc valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $887.27K.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 3 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 6 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 9 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $693.16K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $1.35M 10-Q · filed 2026-08-14 | $2.60M derived: sum of 3 quarters · filed 2026-08-14 | $2.67M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $661.55K 10-Q · filed 2026-05-14 | $1.90M derived: sum of 2 quarters · filed 2026-08-14 | $1.97M derived: sum of 3 quarters · filed 2026-08-14 | $1.35M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $1.24M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-14 | $1.31M derived: sum of 2 quarters · filed 2026-08-14 | $693.16K derived: sum of 3 quarters · filed 2026-08-14 | $1.35M 10-Q · filed 2026-08-14 | $887.27K 10-K · filed 2026-03-30 |
| 2025-09-30 | $70.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | -$549.72K derived: sum of 2 quarters · filed 2025-11-17 | $111.83K 10-Q · filed 2025-11-17 | ||
| 2025-06-30 | -$619.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-09-09 | $41.56K 10-Q · filed 2025-09-09 | |||
| 2025-03-31 | $661.55K 10-Q · filed 2026-05-14 | ||||
| 2024-12-31 | $887.27K 10-K · filed 2026-03-30 | $41.56K 10-Q · filed 2025-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |